XORTX Therapeutics announced that the Japan Patent Office has granted a patent for its XRx-101 program, which focuses on treating acute kidney injury and other organ damage caused by respiratory viral infections. This patent, expected to be valid until 2041, protects the use of xanthine oxidase inhibitors like oxypurinol in Japan, a major pharmaceutical market. The approval strengthens XORTX's intellectual property portfolio and supports potential future partnerships. The company continues to develop treatments for gout and kidney diseases with several patents pending globally.
XORTX Therapeutics' recent patent approval for its XRx-101 program offers context for readers interested in health sector developments. For readers following health stocks, here is Pluang's market snapshot as of Nov 14, 2026 00:01 WIB: Among 150 priced US health-sector stocks, 50 rose and 100 fell. Notable movers include RXRX (Recursion Pharmaceuticals Inc) at USD 3.21 with a -3.75% change and a typical hold time of 23 days, TVTX (Travere Therapeutics Inc.) at USD 49.70 down 3.61%, and CGC (Canopy Growth Corp) at USD 0.55 down 3.56% with 86% sell order activity.
Susan R. Burns, Ph.D., President of the University of Mount Saint Vincent, has been awarded the 2027 Courageous Leadership Award for her visionary and bold leadership. Since 2021, she has led the university through significant transformation, includi...
Solo, a company specializing in privacy-preserving human verification, has integrated its SDK into JellyJelly, a social video app co-founded by Venmo's co-founder. This integration ensures that every JellyJelly account belongs to a real, unique perso...
The U.S. market for AI-enabled ophthalmic diagnostic devices is projected to grow from $72.5 million in 2026 to $267.2 million by 2033, expanding at a 20.5% CAGR. Growth is driven by rising diabetes-related eye diseases, FDA clearances for autonomous...
The global medical display monitors market, valued at $2.8 billion in 2025, is projected to grow to $4.0 billion by 2033 with a CAGR of 4.6%. Growth is fueled by rising adoption of digital imaging systems, demand for accurate diagnostics, and healthc...
Oppenheimer downgraded Enovix from Outperform to Perform as the company expands production in South Korea and shifts focus to drone and smart-eyewear customers. Enovix reported a 38% revenue increase to $11 million in Q3 but saw its adjusted loss wid...
